AbbVie Is Near Its High. Piper Sandler Sees Another 23%

Wiltone Asuncion • 5 minute read
Reviewed by: Michael Douglass
Last updated Nov 20, 2026

@winnond from Getty Images via Canva, @Pavel Danilyuk from Pexels via Canva

Key Takeaways

  • Piper Sandler raised its AbbVie price target to $349 from $303 and kept its Overweight rating, 23% above the Nov. 19 close of $283.54.
  • Piper argues AbbVie deserves a higher multiple, partly on early data for Skyrizi combination drugs, while Skyrizi keeps growing against Johnson & Johnson’s rival psoriasis drugs.
  • At $349, AbbVie would trade at about 19x analysts’ 2028 earnings estimate, close to today’s multiple and well above its 14x five-year average.
  • The stock has already priced in most of the higher multiple Piper wants, so the target depends on 2027 guidance in early February matching the $16.22 a share analysts expect.

AbbVie (ABBV) is up 22% over the past year and trades within 4% of its record close, and Piper Sandler thinks it has further to run. In a note reported on Nov. 18, the firm raised its price target to $349 from $303 and kept its Overweight rating. Shares still fell 2.3% that day as healthcare stocks broadly slipped, then closed at $283.54 on Nov. 19, which puts the upside at 23%.

Skyrizi is at the heart of it, up 22.7% last quarter despite rival psoriasis drugs from Johnson & Johnson (JNJ).

Skyrizi is holding off J&J

On Oct. 30, AbbVie reported third-quarter revenue up 10.3% to $17.4 billion and raised its 2026 adjusted EPS guidance to $13.95-$13.99, in line with the $13.98 analysts expect. Commercial chief Jeff Stewart said on the third-quarter call that “recent oral competition is not having a substantive impact on our in-play patient share,” with Skyrizi still winning about one of every two new or switching psoriasis patients. The newest oral rival is J&J’s Icotyde pill, approved in the U.S. earlier this year, and J&J named its injectable Tremfya among the main drivers of its third-quarter drug sales growth. J&J’s Dec. 8 business review is its next chance to show those drugs taking share.

TIKR tracks 29 analysts on AbbVie. How many say “Buy”?

See the full breakdown of Buy, Hold, and Sell ratings on AbbVie, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See AbbVie’s Analyst Ratings

Piper is betting on the combinations

Piper says AbbVie’s sales and EBITDA growth through the end of the decade can create value on its own, and it expects the stock’s multiple to expand too. Part of that, Piper says, is growing visibility on Skyrizi combination drugs in inflammatory bowel disease, which could extend the franchise’s life. R&D chief Roopal Thakkar said Skyrizi plus ABBV-382 “resulted in a near doubling of endoscopic remission at week 24 compared to either monotherapy” in Crohn’s disease. That’s Phase 2 data, and Thakkar said Phase 3 trials could start as early as the end of 2027, though he didn’t commit to that timing. Barclays lifted its target to $335 from $325 on Nov. 16.

Does $349 add up?

The 29 analysts covering AbbVie have a consensus target of $314, up from $244 a year ago.

Line chart from TIKR of AbbVie's analysts' consensus (mean) price target, $ per share, last year.
AbbVie (ABBV): analysts’ consensus (mean) price target, $ per share, last year (TIKR)

They expect normalized EPS to climb from $13.98 in 2026 to $18.01 in 2028, but the 2027 estimate, $16.22, is no higher than it was three months ago.

Bar chart from TIKR of AbbVie's normalized EPS, actual and consensus estimates, $ per share, fiscal 2024-2028.
AbbVie (ABBV): normalized EPS, actual and consensus estimates, $ per share, fiscal 2024-2028 (TIKR)

On 2028 estimates, $349 works out to about 19x earnings, above the roughly 18x forward P/E at the Nov. 19 close and well above the stock’s 14x average over the past five years. Most of the gain would come from earnings growing about 15% from the next twelve months to 2028, with the multiple rising from about 18x to about 19x.

Line chart from TIKR of AbbVie's forward (NTM) P/E, last 5 years.
AbbVie (ABBV): forward (NTM) P/E, last 5 years (TIKR)

AbbVie has rarely traded this high: its five-year peak was near 20x, in October 2025.

The rerating already happened

The main risk is 2027, when management expects the Apogee deal to cut adjusted EPS by about $0.46 and Vraylar’s Medicare-set price takes effect. Piper’s target can work, but the stock has already priced in most of the higher multiple Piper argues for, so getting there depends on earnings arriving on time. CEO Rob Michael told analysts, “we expect to deliver top-tier growth again next year.” AbbVie’s 2027 guidance, due with fourth-quarter results in early February, has to come in at or above $16.22 a share to keep $349 in reach.

So what is AbbVie stock actually worth?

TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what AbbVie could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.

Value AbbVie for free

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!

Join thousands of investors worldwide who use TIKR to supercharge their investment analysis.

Sign Up for FREENo credit card required